MedTrace Logo

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2018-08-02

No results posted yet for this study

Summary

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Conditions

  • Solid Tumor
  • Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
  • Tenosynovial Giant Cell Tumor

Interventions

DRUG

PLX7486 TsOH

PLX7486 TsOH capsules, 50mg

Sponsors & Collaborators

  • Plexxikon

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-01-24
Completion
2018-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01804530 on ClinicalTrials.gov